AbbVie sales blow past forecasts, fueled by Humira
(Reuters) – AbbVie, which this month walked away from a $55 billion deal to buy Dublin drugmaker Shire, on Friday reported quarterly revenue and earnings well above Wall Street expectations, fueled by soaring sales of its Humira arthritis drug. The Chicago drugmaker, which significantly boosted its full-year earnings forecast, said it earned $506 million, or 31 cents per share, in the third quarter. That compared with $964 million, or 60 cents per share, in the year-earlier period. Company sales rose 7.8 percent to $5.02 billion, topping the average analyst estimate of $4. …
